

NET SALES AS OF SEPTEMBER 30, 2018

Longjumeau, November 7, 2018

PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales as of September 30, 2018.

The PCAS Group had generated consolidated net sales of €144.2 million as of September 30, 2018, representing a decrease of 5.6% compared to the same period of the previous financial year (-4.3% at constant exchange rates).

| In millions of euros | 2018 | 2017 | Growth in % | 2018 At a constant exchange rate | Growth in % |
|-------------------------------------|--------------|--------------|---------------|----------------------------------|---------------|
| Net sales as of 30 September | 144,2 | 152,7 | -5,6% | 146,1 | -4,3% |
| <i>Pharmaceutical Synthesis</i> | <i>88,9</i> | <i>101,8</i> | <i>-12,6%</i> | <i>90,2</i> | <i>-11,4%</i> |
| <i>Fine Specialty Chemicals</i> | <i>55,3</i> | <i>50,9</i> | <i>8,6%</i> | <i>55,9</i> | <i>9,9%</i> |

Pharmaceutical Synthesis

The Pharmaceutical Synthesis business generated €88.9 million, down 12.6% compared to 2017 (-11.4% at constant exchange rates), partly due to first half-year multi-stage productions and projects being put back, the sales of which should spread over the last quarter.

Fine Specialty Chemicals

Net sales of Fine Specialty Chemicals totaled €55.3 million, up 8.6% on 2017 (+9.9% at constant exchange rates), with growth in both Performance Additives (Lubricants) and Advanced Specialty Chemicals for the micro-electronics part.

Outlook

The Group's net sales in 2018 are expected to be close to those of 2017. Operational difficulties have been faced over the last 2 months, reducing some plants production capacities. Thus, the Group's results could be significantly affected if these issues remain, given the high level of activity towards the end of the year or if the American currency were to weaken against the euro.



NEXT FINANCIAL DISCLOSURE:

2018 Results on Wednesday, February 20, 2019

ABOUT PCAS

PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in leading-edge segments. PCAS generated net sales of €218.3 million in 2017 and employs close to 1 100 people in six countries.

To find out more about PCAS, visit: www.pcas.com

PCA
LISTED
EURONEXT

PCAS

Vincent Touraille / Eric Moissenot

Tel. : +33 1 69 79 61 32

www.pcas.com

NewCap

Emmanuel Huynh / Louis-Victor Delouvrier

Financial communication and Investor Relations

Tel. : +33 1 44 71 98 53

pcas@newcap.eu